I'll take further discussion over to the GT thread...
Subject 25613
...but while I'm here, one last post for the
current subthread...
Yeah Tom, I know all about misery, watch yourself
with that ARIA, I'm pretty bold so I've loaded up
(still playing with house money) and I've guessed
that the odds of finding ARGENT partners or just
selling ARGENT are greater than going bankrupt--
Hoechst probably would not let that happen anyway.
But be careful. For all I know they're writing
personal checks over there to cover salaries...
If you ever come across any articles which
compare the various GT regulation schemes drop it
off. I got sucked into my stock partly because they
dropped a lot of names in the Annual, and there
were a couple of impressive papers where they
showed their dimerizer works great. If you've not
seen the hGH in mice paper at PNAS.com, check it
out--I'd love to hear your input--and as far as
"sustained expression and relative lack of immunogenicity",
well I think Ariad/Genovo are doing really well here,
more than ten months and immunocompetent mice.
But it's tough reading for me.
I was really impressed, but maybe I'm dazzled a
bit too easily.
Signing off now--for as long as I can stay away;
see my updated personal profile for my amusing little
farewell.
Oh if anybody wants a copy of the article, PM me.
I'll be back in a week or two, I cant usually stay
away from the quotes for very long...forever hopeful. |
